Inventor
WEISS DAHLIA
US11 patents
Patents
11 patentsUS11530229B2Dec 20, 2022
Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
NURIX THERAPEUTICS INC12 citations84
US11464802B2Oct 11, 2022
3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
NURIX THERAPEUTICS INC14 citations84
US11401267B2Aug 2, 2022
Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
NURIX THERAPEUTICS INC11 citations84
US11866442B2Jan 9, 2024
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
NURIX THERAPEUTICS INC5 citations83
US11479556B1Oct 25, 2022
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
NURIX THERAPEUTICS INC9 citations83
US11951133B2Apr 9, 2024
3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
NURIX THERAPEUTICS INC2 citations71
US12485144B2Dec 2, 2025
3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
NURIX THERAPEUTICS INC1 citations62
US12234230B2Feb 25, 2025
Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
NURIX THERAPEUTICS INC1 citations62
US12049471B2Jul 30, 2024
Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
NURIX THERAPEUTICS INC1 citations61
US12583862B2Mar 24, 2026
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
NURIX THERAPEUTICS INC0 citations60
US12528814B2Jan 20, 2026
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
NURIX THERAPEUTICS INC0 citations50